ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1890

Daily Management of Patients with Axial Spondyloarthritis: Self-monitoring of Disease Activity with a Smartphone App Is Feasible – a Proof of Concept Study
Abstract Number: 1061

Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
Abstract Number: 2036

Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Abstract Number: 0918

Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Abstract Number: 1022

Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
Abstract Number: 1423

Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study
Abstract Number: 0966

Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3
Abstract Number: 1961

Decreased Visits in RISE Practices Due to the SARS-CoV-2 Global Pandemic
Abstract Number: 0423

Defining Ear Chondritis: Data from 685 Patients with Relapsing Polychondritis
Abstract Number: 0391

Defining the Optimal Disease Duration of Early Diffuse Systemic Sclerosis for Clinical Trial Design
Abstract Number: 1939

Definitions and Reliability Assessment of Chronic Ultrasound Lesions of the Axillary Artery in Giant Cell Arteritis: A Study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
Abstract Number: 0308

Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
Abstract Number: 1847

Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus
Abstract Number: 0837

Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Abstract Number: 0848

Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].